Related Experiment Video
Updated: Aug 28, 2025
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
Yuying Wang1, Yuetian Yu1, Haojie Zhang1
1Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Insights
Metabolic associated fatty liver disease (MAFLD) patients show similar or higher cardiovascular risks than nonalcoholic fatty liver disease (NAFLD) patients. However, males with NAFLD had a higher risk of chronic kidney disease (CKD).
Area of Science:
- Hepatology
- Cardiology
- Nephrology
Background:
- Metabolic associated fatty liver disease (MAFLD) is a proposed redefinition of nonalcoholic fatty liver disease (NAFLD), emphasizing metabolic dysfunction.
- Understanding the distinct clinical burdens of MAFLD versus NAFLD is crucial for patient management.
Purpose of the Study:
- To compare the cardiovascular and renal disease burden between patients diagnosed with MAFLD and NAFLD.
Main Methods:
- A cohort of 12,183 participants from East China was analyzed.
- Cardiovascular risk was assessed using the Framingham risk score and history of cardiovascular diseases (CVD).
- Renal burden was evaluated by estimated glomerular filtration rate (eGFR) and the prevalence of chronic kidney disease (CKD).
Main Results:
- MAFLD patients exhibited higher risks of hypertension, dyslipidemia, diabetes, overweight/obesity, and central obesity compared to NAFLD patients.
- MAFLD patients had similar or increased risk coefficients for the Framingham risk score and higher odds of previous CVD compared to NAFLD patients.
- While males with NAFLD showed a higher odds ratio for CKD, this association was not significant for MAFLD patients or for females in either group.
Conclusions:
- MAFLD is associated with a comparable or elevated risk of current and future cardiovascular disease when contrasted with NAFLD.
- The risk of chronic kidney disease (CKD) appears higher in males with NAFLD than in males with MAFLD.
Background/Purpose:
Metabolic associated fatty liver disease (MAFLD) was proposed as a new definition to put emphasis on the metabolic aspects of nonalcoholic fatty liver disease (NAFLD). We aim to compare the cardiovascular and renal burden between MAFLD and NAFLD patients.
Methods:
12183 participants were enrolled in East China. The cardiovascular burden (Framingham risk score and previous cardiovascular diseases (CVD)) and renal burden (eGFR and chronic kidney disease (CKD)) were measured.
Results:
The risk of hypertension, dyslipidemia, diabetes, overweight/obesity, and central obesity of MAFLD patients were higher than those of NAFLD. Patients with MAFLD have a similar or higher beta coefficients in Framingham risk score [beta (95%CI): male 0.062 (0.055,0.069) vs 0.041 (0.033,0.048); female 0.014 (0.012,0.016) vs 0.012 (0.01,0.014)], and higher odds ratio in previous CVD [odds ratio (95%CI): male 1.50 (1.22,1.85) vs 1.35 (1.1,1.66); female 1.58 (1.33,1.87) vs 1.45 (1.22,1.72)], compared with those with NAFLD. However, compared with males with MAFLD, the odds ratio of CKD was higher in those with NAFLD [eGFR: -2.731 (-3.422, -2.041) vs-3.578 (-4.268, -2.887). CKD: 1.44 (1.05,1.96) vs 1.56 (1.14,2.12)]. In female, CKD was only marginally associated with NAFLD [0.8 (0.62,1.02), P=0.075], but not MAFLD [0.87 (0.68,1.11), P=0.268].
Conclusions:
Patients with MAFLD have a similar or higher risk of future and previous CVD compared with those with NAFLD, but the risk of CKD was higher in male with NAFLD.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
01:24Chronic Kidney Disease II: Clinical Manifestations